Diabetic Nephropathy Market Forecasts to 2030 – Global Analysis By Type (Type-1 Diabetes, Type-2 Diabetes and Other Types), By Diagnosis Type (Blood Test, Urine Test, Imaging Test, Renal Function Testing, Kidney Biopsy and Other Diagnosis Types), By Treat

Diabetic Nephropathy Market Forecasts to 2030 – Global Analysis By Type (Type-1 Diabetes, Type-2 Diabetes and Other Types), By Diagnosis Type (Blood Test, Urine Test, Imaging Test, Renal Function Testing, Kidney Biopsy and Other Diagnosis Types), By Treatment, Route of Administration, Distribution Channel, End Users and By Geography

According to Stratistics MRC, the Global Diabetic Nephropathy Market is accounted for $2.7 billion in 2023 and is expected to reach $4.1 billion by 2030 growing at a CAGR of 5.8% during the forecast period. Diabetic Nephropathy is a kidney condition resulting from diabetes, characterized by kidney damage due to prolonged high blood sugar levels. Its early detection through regular screening allows for timely intervention, including lifestyle modifications and medications, preventing or slowing progression and reducing the risk of complications associated with advanced kidney disease.

According to the International Diabetes Federation (IDF), 40% of diabetics may experience kidney failure in its ultimate stages. Furthermore, about 80% of end-stage renal failure is caused by diabetes and hypertension, either together or individually.

Market Dynamics:

Driver:

Increased awareness and proactive screening programs

Awareness campaigns educate individuals about the risks of kidney complications associated with diabetes, more people are encouraged to undergo regular screenings for early detection. Early identification enables prompt intervention and management, potentially slowing the progression of diabetic nephropathy and reducing associated complications. Proactive screening not only contributes to better patient outcomes but also enhances the overall effectiveness of healthcare systems in managing diabetic nephropathy. This driver underscores the importance of preventive healthcare measures, empowering individuals to take proactive steps in addressing diabetic nephropathy and promoting better long-term health outcomes.

Restraint:

High treatment costs

The complex nature of managing diabetic nephropathy, which may involve medications, lifestyle modifications, and, in severe cases, renal replacement therapies, contributes to elevated healthcare expenses. The financial burden associated with consistent medical appointments, medications, and potential dialysis or kidney transplantation can limit access to optimal care, especially for individuals with limited financial resources. This economic barrier may result in delayed or inadequate treatment, adversely impacting patient outcomes.

Opportunity:

Government initiatives for diabetes management

As governments globally prioritize public health, initiatives aimed at preventing and managing diabetes directly benefit the market. Policies supporting awareness campaigns, diabetes education, and accessible screening programs contribute to early detection and intervention in diabetic nephropathy cases. Government-backed healthcare programs and subsidies for medications can enhance patient access to treatment, fostering a more conducive environment for market growth. Collaboration between healthcare authorities and the pharmaceutical industry to align with these initiatives not only addresses the societal burden of diabetes but also creates a supportive framework for the expansion of diabetic nephropathy management solutions.

Threat:

Side effects associated with certain medications

Pharmaceutical interventions play a crucial role in managing diabetic nephropathy, the potential adverse effects of medications may lead to patient apprehension, non-compliance, or discontinuation of treatment. Side effects such as gastrointestinal issues, hypoglycemia, and renal complications can compromise the overall well-being of patients. This threat underscores the importance of developing and prescribing medications with favorable safety profiles. Pharmaceutical companies and healthcare providers must prioritize research and innovation to minimize side effects, ensuring that the benefits of treatment outweigh potential risks.

Covid-19 Impact:

The Covid-19 pandemic has had a multifaceted impact on the Diabetic Nephropathy Market. Disruptions in healthcare services, patient hesitancy to seek non-urgent medical care, and diversion of resources to pandemic management have collectively affected the diagnosis and management of diabetic nephropathy. However, the pandemic has also emphasized the importance of proactive management and highlighted opportunities for telemedicine and digital health solutions to enhance remote monitoring and patient care in the diabetic nephropathy landscape.

The urine test segment is expected to be the largest during the forecast period

The urine test segment is expected to have a lucrative growth. These tests, such as albuminuria and proteinuria assessments, help in early detection of kidney damage caused by diabetes. Monitoring the presence of abnormal levels of proteins in the urine aids healthcare professionals in assessing the progression of nephropathy. Regular urine testing allows for timely intervention and personalized treatment plans, contributing to better management of diabetic nephropathy and improved patient outcomes. It serves as a non-invasive and cost-effective diagnostic tool, supporting effective healthcare strategies in combating this complication of diabetes.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These healthcare institutions provide essential services, including diagnostic screenings, consultations with nephrologists, and access to a range of therapeutic interventions. Hospitals also facilitate more advanced treatments like dialysis and kidney transplantation for severe cases. Additionally, they serve as hubs for patient education, contributing to increased awareness and proactive management of diabetic nephropathy. The collaborative efforts of hospitals, healthcare professionals, and patients are critical in addressing the challenges posed by diabetic nephropathy and improving patient outcomes.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region's advanced medical research capabilities contribute to early detection, innovative therapies, and a robust pharmaceutical market. Government initiatives, healthcare policies, and a heightened awareness of diabetes further support the market's growth. With a growing aging population and a focus on preventive healthcare, North America continues to be a key player in shaping advancements and solutions for the effective management of diabetic nephropathy.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The region's rising prevalence of diabetes, particularly in countries like China and India, amplifies the demand for diabetic nephropathy management. Government initiatives, improving healthcare infrastructure, and growing investments in research and development contribute to the market's expansion. As the region grapples with the diabetes epidemic, the Diabetic Nephropathy Market in Asia Pacific is positioned for substantial growth, presenting opportunities for healthcare providers and pharmaceutical companies to address the evolving healthcare needs of the population.

Key players in the market

Some of the key players in Diabetic Nephropathy market include F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GlaxoSmithKline Plc., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Bayer AG and Bristol Myers Squibb Company.

Key Developments:

In March 2023, Novartis announced that it had submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for renoprotective effects of sevelamer carbonate, a phosphate binder, for the treatment of diabetic nephropathy.

In January 2023, Boehringer Ingelheim and Eli Lilly and Company announced that US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. These tablets have been investigated as a possible therapy to reduce the chance of cardiovascular death and kidney disease progression in adults with chronic kidney disease.

In December 2022, Bayer launched Finerenone under the brand name Kerendia in India. Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Types Covered:
• Type-1 Diabetes
• Type-2 Diabetes
• Other Types

Diagnosis Types Covered:
• Blood Test
• Urine Test
• Imaging Test
• Renal Function Testing
• Kidney Biopsy
• Other Diagnosis Types

Treatments Covered:
• Medication
• Kidney Dialysis
• Transplant

Route of Administrations Covered:
• Oral
• Parental
• Other Route of Administrations

Distribution Channels Covered:
• Online Pharmacy
• Retail Pharmacy

End Users Covered:
• Hospitals
• Homecare
• Speciality Centres
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements